Impact of Disease Burden on Cryoablation Prostate-specific Antigen Outcomes

Urology

Volumn 75, Issue 2, 2010, Pages 478-481

  Levy, David A ^a   Li, Jianbo ^a   Jones, Stephen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CRYOABLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE SURGERY; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CRYOSURGERY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 75349106097     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.054     Document Type: Article

References (16)

1. Karakiewicz P.I., Bhojani N., Capitanio U., et al. External validation of the updated Partin tables in a cohort of North American men. J Urol 180 (2008) 898-902
2. Bhojani N., Salomon L., Capitanio U., et al. External validation of the updated Partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys 73 (2009) 347-352
3. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol 21 (2003) 2163-2172
4. Molitierno J., Evans A., Mohler J.L., et al. Characterization of biochemical recurrence after radical prostatectomy. Urol Int 77 (2006) 130-134
5. Sengupta S., Christensen C.M., Zinke H., et al. Detectable prostate-specific antigen 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol 176 (2006) 559-563
6. Lin D.D., Schultz D., Renshaw A.A., et al. Predictors of short postoperative prostate specific antigen doubling time for patients diagnosed during the PSA era. Urology 65 (2005) 528-532
7. Teeter A.E., Banez L.L., Presti J.C., et al. What are factors associated with short prostate specific antigen doubling time after radical prostatectomy?. A report from the SEARCH database group. J Urol 180 (2008) 1980-1984
8. Naselli A., Introini C., Andreatta R., et al. Prognostic factors of persistently detectable PSA after radical prostatectomy. Int J Urol 16 (2009) 82-86
9. Shikanov S.A., Thong A., Gofrit O.N., et al. Robotic laparoscopic radical prostatectomy for biopsy Gleason 8 to 10: prediction of favorable pathologic outcome with preoperative parameters. J Endourol 22 (2008) 1477-1481
10. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 679-684
11. Freedland S.J., Aronson W.J., Terris M.K., et al., The SEARCH Database Study Group. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 169 (2003) 2136-2141
12. Harnden P., Shelly M.D., Naylor B., et al. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence?. A systematic review. Eur Urol 54 (2008) 728-739
13. Sebo T.J., Bock B.J., Cheville J.C., et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163 (2000) 179-180
14. Spalding A.C., Daignault S., Sandler H.M., et al. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology 69 (2007) 936-940
15. Levy D.A., Pisters L.L., and Jones J.S. Primary cryoablation Nadir prostate specific antigen and biochemical failure. J Urol 182 (2009) 931-937
16. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol 21 (2003) 2163-2172